>
Widow of killed fire chief not satisfied with Secret Service suspensions...
Gunman leaves multiple injured at church after shooting cop at Kentucky's Blue Grass Airport
One year later: White House highlight Trump's legacy on anniversary of assassination attempt
Arizona homeowner fined by petty HOA for act of kindness during extreme heat
Magic mushrooms may hold the secret to longevity: Psilocybin extends lifespan by 57%...
Unitree G1 vs Boston Dynamics Atlas vs Optimus Gen 2 Robot– Who Wins?
LFP Battery Fire Safety: What You NEED to Know
Final Summer Solar Panel Test: Bifacial Optimization. Save Money w/ These Results!
MEDICAL MIRACLE IN JAPAN: Paralyzed Man Stands Again After Revolutionary Stem Cell Treatment!
Insulator Becomes Conducting Semiconductor And Could Make Superelastic Silicone Solar Panels
Slate Truck's Under $20,000 Price Tag Just Became A Political Casualty
Wisdom Teeth Contain Unique Stem Cell That Can Form Cartilage, Neurons, and Heart Tissue
Hay fever breakthrough: 'Molecular shield' blocks allergy trigger at the site
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.